Sestak, I., Zhang, Y., Schroeder, B. E., Schnabel, C. A., Dowsett, M., Cuzick, J., Sgroi, D. (2016) Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer. CLINICAL CANCER RESEARCH, 22 (20). pp. 5043-5048. ISSN 1078-0432

Full text not available from this repository.

Abstract

Purpose: Previous results from the TransATAC study demonstrated that both the Breast Cancer Index (BCI) and the Oncoty-peDX Recurrence Score (RS) added significant prognostic information to clinicopathologic factors over a 10-year period. Here, we examined cross-stratification between BCI and RS to directly compare their prognostic accuracy at the individual patient level. Experimental Design: A total of 665 patients with hormone receptor-positive (HR+) and lymph node-negative disease were included in this retrospective analysis. BCI and RS risk groups were determined using predefined clinical cut-off points. Kaplan-Meier estimates of 10-year risk of distant recurrence (DR) and log-rank tests were used to examine cross-stratification between BCI and RS. Results: As previously reported, both RS and BCI were significantly prognostic in years 0 to 10. BCI provided significant additional prognostic information to the Clinical Treatment Score (CTS) plus RS (Delta LR-chi(2) = 11.09; P < 0.001), whereas no additional prognostic information was provided by RS to CTS plus BCI (Delta LR-chi(2) = 2.22; P = 0.1). Restratification by BCI of the low and intermediate RS risk groups led to subgroups with significantly different DR rates (P < 0.001 and P = 0.003, respectively). In contrast, restratified subgroups created by RS of BCI risk groups did not differ significantly. Conclusions: In this retrospective analysis, BCI demonstrated increased prognostic accuracy versus RS. Notably, BCI identified subsets of RS low and RS intermediate risk patients with significant and clinically relevant rates of DR. These results indicate that additional subsets of women with HR+, lymph node-negative breast cancer identified by BCI may be suitable candidates for adjuvant chemotherapy or extended endocrine therapy. (C) 2016 AACR.

Item Type:	Article
Authors (ICR Faculty only):	Dowsett, Mitch
All Authors:	Sestak, I., Zhang, Y., Schroeder, B. E., Schnabel, C. A., Dowsett, M., Cuzick, J., Sgroi, D.
Additional Information:	ISI Document Delivery No.: DZ1WP Times Cited: 1 Cited Reference Count: 20 Sestak, Ivana Zhang, Yi Schroeder, Brock E. Schnabel, Catherine A. Dowsett, Mitch Cuzick, Jack Sgroi, Dennis AstraZeneca; National Institute for Health Research Biomedical Research at the Royal Marsden (London, United Kingdom); Cancer Research UK [C569/A16891] This work was supported by Cancer Research UK (C569/A16891), AstraZeneca, and the National Institute for Health Research Biomedical Research at the Royal Marsden (London, United Kingdom). 1 0 AMER ASSOC CANCER RESEARCH PHILADELPHIA CLIN CANCER RES
Uncontrolled Keywords:	LATE-DISTANT RECURRENCE ESTROGEN-RECEPTOR GENE-EXPRESSION ONCOTYPE DX PAM50 RISK PREDICTION ASSAY TAMOXIFEN TRANSATAC IHC4
Research teams:	ICR divisions > Breast Cancer Research > Endocrinology ICR divisions > Molecular Pathology > Endocrinology
Depositing User:	Barry Jenkins
Date Deposited:	21 Nov 2016 13:26
Last Modified:	21 Nov 2016 13:26
URI:	http://publications.icr.ac.uk/id/eprint/15437

Actions (login required)

View Item